Recently, analysis of circulating tumor DNA revealed the emergence of distinct KRAS activating mutations (G12A, Q61H, and A146T) in three of 43 EGFR-mutant NSCLC patients with acquired activating mutations [41]. This evidence concerns the gene EGFR and neoplasm.